Jupiter Topco LLC Acquires Shares of 1,138,783 DexCom, Inc. $DXCM

Jupiter Topco LLC bought a new position in DexCom, Inc. (NASDAQ:DXCM) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 1,138,783 shares of the medical device company’s stock, valued at approximately $76,696,000. Jupiter Topco LLC owned approximately 0.30% of DexCom as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. EFG International AG bought a new position in DexCom in the 2nd quarter valued at approximately $889,000. Ancora Advisors LLC bought a new stake in shares of DexCom in the 2nd quarter worth $66,000. Primecap Management Co. CA bought a new stake in shares of DexCom in the 2nd quarter worth $12,931,000. Canada Pension Plan Investment Board purchased a new position in shares of DexCom in the second quarter worth $71,040,000. Finally, Parkman Healthcare Partners LLC bought a new position in shares of DexCom during the second quarter valued at $36,017,000. Institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

DXCM has been the topic of several recent analyst reports. JPMorgan Chase & Co. increased their price objective on DexCom from $65.00 to $82.00 and gave the company a “neutral” rating in a research report on Friday, July 31st. William Blair raised DexCom to a “strong-buy” rating in a research report on Friday, May 15th. TD Cowen restated a “buy” rating on shares of DexCom in a research note on Friday, July 31st. Deutsche Bank Aktiengesellschaft started coverage on shares of DexCom in a report on Tuesday, June 23rd. They set a “buy” rating and a $86.00 price target on the stock. Finally, Stifel Nicolaus set a $95.00 price target on shares of DexCom and gave the stock a “buy” rating in a research note on Friday, July 31st. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, DexCom has an average rating of “Moderate Buy” and a consensus price target of $88.71.

Insider Buying and Selling

In related news, EVP Michael Jon Brown sold 1,700 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $75.55, for a total transaction of $128,435.00. Following the completion of the transaction, the executive vice president directly owned 106,353 shares in the company, valued at approximately $8,034,969.15. The trade was a 1.57% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of the stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $76.32, for a total transaction of $2,042,017.92. Following the completion of the sale, the insider directly owned 328,970 shares of the company’s stock, valued at $25,106,990.40. This represents a 7.52% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 73,035 shares of company stock worth $5,446,673. Corporate insiders own 0.28% of the company’s stock.

DexCom Trading Up 0.4%

Shares of DexCom stock opened at $89.29 on Friday. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $92.59. The company’s fifty day simple moving average is $78.84 and its 200-day simple moving average is $71.47. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. The stock has a market capitalization of $33.69 billion, a PE ratio of 35.29, a P/E/G ratio of 1.50 and a beta of 1.41.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%.The firm had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. During the same period in the prior year, the business posted $0.48 EPS. DexCom’s revenue was up 13.1% on a year-over-year basis. As a group, equities analysts anticipate that DexCom, Inc. will post 2.64 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.